Paige, the global leader in AI-based diagnostic software in pathology, today launched its latest product, Paige Breast Lymph Node, an AI medical device software that helps pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review. The product was unveiled at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place March 19-24, 2022.

Determining whether cancer in the breast has spread to the lymphatic system is critical to a patient’s diagnosis and planned treatment. Due to the size of the tissue area and the size of the small micro-metastases, a pathologist’s accurate assessment of a lymph node slide can be tedious and time-consuming.

Designed to increase the accuracy and efficiency in the detection of breast cancer metastases that are most at-risk for being missed, Paige Breast Lymph Node leverages AI to empower pathologists to identify tumor metastases of any size, including small micrometastases, more efficiently and reliably. It is designed to enhance diagnostic accuracy for the most subtle metastatic foci and has over 98% slide level sensitivity to detect metastases of any size. A positive indication of metastatic breast cancer will be displayed at the individual lymph node level with Paige’s proprietary TissueMap, which highlights all regions on a slide that are suspicious for cancer. In addition, both slides and cases with suspected positive lymph nodes are highlighted, facilitating their prioritization and efficient review by the pathologist.

“Accurate detection of breast cancer metastases is paramount for physicians and their patients, but it can be a laborious, manual task for pathologists,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “Paige Breast Lymph Node offers pathologists a quicker and more efficient way to analyze large quantities of lymph node tissue, as well as peace of mind for them and their patients.”